Key statistics
As of last trade Candel Therapeutics Inc (CADL:NMQ) traded at 7.94, -44.48% below its 52-week high of 14.30, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.80 |
---|---|
High | 8.05 |
Low | 7.47 |
Bid | 7.94 |
Offer | 7.97 |
Previous close | 7.68 |
Average volume | 346.48k |
---|---|
Shares outstanding | 32.08m |
Free float | 22.19m |
P/E (TTM) | -- |
Market cap | 246.41m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:12 BST.
More ▼
- Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Candel Therapeutics to Join Russell 3000® Index
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
More ▼